Comparative Pharmacology
Head-to-head clinical analysis: FALLBACK SOLO versus PREVIFEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FALLBACK SOLO versus PREVIFEM.
FALLBACK SOLO vs PREVIFEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FALLBACK SOLO is a small molecule inhibitor of the Hedgehog signaling pathway. It binds to and inhibits Smoothened (SMO), a transmembrane protein that activates the GLI transcription factors. This inhibition blocks the aberrant activation of the Hedgehog pathway, which is implicated in the growth of certain cancers.
PREVIFEM is a combination of ethinyl estradiol, an estrogen, and norgestimate, a progestin. It inhibits ovulation by suppressing gonadotropin release from the pituitary (FSH and LH). Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium.
100 mg orally once daily
One tablet (0.075 mg norgestrel and 0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 consecutive days, followed by 7 placebo tablets.
None Documented
None Documented
Terminal half-life: 12 hours (range 10–14 h); clinical context: once-daily dosing achieves steady state in 2.5 days
20-24 hours; steady-state reached in 5 days
Renal: 80% unchanged; fecal: 15% as metabolites; biliary: 5%
Renal (60% as metabolites, <10% unchanged), fecal (30%), biliary (10%)
Category C
Category C
Emergency Contraceptive
Emergency Contraceptive